Characterization of the steric defense of the HIV‐1 gp41 N‐trimer region

During viral entry, HIV gp41 adopts a transient conformation called the “prehairpin intermediate” in which a highly conserved therapeutic target, the N‐trimer, is exposed. Despite extensive discovery efforts, potent and broadly neutralizing antibodies that target the N‐trimer are elusive. We previously demonstrated the N‐trimer is protected by a steric block that prevents large proteins, such as antibodies, from accessing it. Here we further characterize the steric block and identify its source. To study the N‐trimer steric accessibility, we produced two sets of C‐peptide inhibitors (a potent inhibitor targeting the N‐trimer) fused to cargo proteins of increasing size facing either the virus or cell side of the prehairpin intermediate. Both bulky inhibitor sets show a steric block, but the effect is more pronounced with virus‐side cargo. Additionally, both sets maintain their potencies in a modified entry assay that removes possible sources of target cell steric hindrance. These results implicate a viral source, likely gp120, as the primary component of the steric block. In addition, we studied the steric accessibility of the “pocket” region of the N‐trimer, a highly attractive drug and vaccine target. We demonstrated a pocket‐specific antibody, D5, is more potent as an scFv than as a full‐length IgG, suggesting the N‐trimer steric restriction extends to the pocket. This characterization will facilitate the design of sterically restricted antigens that mimic the steric environment of the N‐trimer in the prehairpin intermediate and are capable of inducing potent and broadly neutralizing antibodies that circumvent the N‐trimer steric block.

[1]  Hong-Bo Pang,et al.  Peptide mimic of the HIV envelope gp120-gp41 interface. , 2008, Journal of molecular biology.

[2]  Michael S. Kay,et al.  Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.

[3]  B. Haynes,et al.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates , 2006, Expert review of vaccines.

[4]  H. I. Henderson,et al.  The temperature arrested intermediate of virus-cell fusion is a functional step in HIV infection , 2006, Virology Journal.

[5]  Gennaro Ciliberto,et al.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Brett D. Welch,et al.  Steric Accessibility of the HIV-1 gp41 N-trimer Region* , 2005, Journal of Biological Chemistry.

[7]  Raghavan Varadarajan,et al.  Characterization of gp120 and Its Single-Chain Derivatives, gp120-CD4D12 and gp120-M9: Implications for Targeting the CD4i Epitope in Human Immunodeficiency Virus Vaccine Design , 2005, Journal of Virology.

[8]  D. Hazuda,et al.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp 41 epitope , 2005 .

[9]  J. Sodroski,et al.  Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Stamatatos,et al.  N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies , 2004, Journal of Virology.

[11]  G. Ciliberto,et al.  Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. , 2004, Journal of immunological methods.

[12]  C. Weiss HIV-1 gp41: mediator of fusion and target for inhibition. , 2003, AIDS reviews.

[13]  Christoph Grundner,et al.  Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[14]  Christoph Grundner,et al.  Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120 , 2003, Cell.

[15]  C. Bewley,et al.  Covalent Trimers of the Internal N-terminal Trimeric Coiled-coil of gp41 and Antibodies Directed against Them Are Potent Inhibitors of HIV Envelope-mediated Cell Fusion* , 2003, Journal of Biological Chemistry.

[16]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[17]  Nga Nguyen,et al.  Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites , 2003, Journal of Virology.

[18]  Robert Blumenthal,et al.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Zolla-Pazner,et al.  Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates , 2002, Journal of Virology.

[20]  Garrett M. Morris,et al.  Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.

[21]  Michael S. Kay,et al.  Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.

[22]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[23]  G. Melikyan,et al.  Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion , 2000, The Journal of cell biology.

[24]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[25]  J. Sodroski,et al.  Enhanced Expression, Native Purification, and Characterization of CCR5, a Principal HIV-1 Coreceptor* , 1999, The Journal of Biological Chemistry.

[26]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[27]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[28]  T. Matthews,et al.  Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides , 1998, Journal of Virology.

[29]  K. Tan,et al.  Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[31]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[32]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[33]  D O Morgan,et al.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.

[34]  R. Connor,et al.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.

[35]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[36]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Andino,et al.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses , 1994, Journal of virology.

[38]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[39]  Shibo Jiang,et al.  HIV-1 inhibition by a peptide , 1993, Nature.

[40]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Littman,et al.  Packaging system for rapid production of murine leukemia virus vectors with variable tropism , 1992, Journal of virology.

[42]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.